119 related articles for article (PubMed ID: 9892382)
1. Subcutaneous erythropoietin therapy: efficacy and economic implications.
Kaufman JS
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S147-51. PubMed ID: 9892382
[TBL] [Abstract][Full Text] [Related]
2. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravenous and subcutaneous erythropoietin in patients on hemodialysis and continuous ambulatory peritoneal dialysis.
Lai PC; Wu MS; Huang JY; Huang CC; Leu ML
Changgeng Yi Xue Za Zhi; 1994 Jun; 17(2):105-12. PubMed ID: 8069732
[TBL] [Abstract][Full Text] [Related]
8. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
9. Potential cost savings of erythropoietin administration in end-stage renal disease.
Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR
Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342
[TBL] [Abstract][Full Text] [Related]
10. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
Besarab A
Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):13-22. PubMed ID: 8352267
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
Besarab A; Flaharty KK; Erslev AJ; McCrea JB; Vlasses PH; Medina F; Caro J; Morris E
J Am Soc Nephrol; 1992 Mar; 2(9):1405-16. PubMed ID: 1627763
[TBL] [Abstract][Full Text] [Related]
13. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
14. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
Abreo K; Lubom JA; Collier L; Fleming D; Work J
Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
Raja R; Bloom E; Goldstein M; Johnson R
ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
[TBL] [Abstract][Full Text] [Related]
19. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
[TBL] [Abstract][Full Text] [Related]
20. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
Trakarnvanich T; Thitiarcharkul S
J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
